


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**


1. (Currently amended) A synthesized oligourea comprising ~~a basic-arginine rich region of Tat~~ the following structure:



wherein  $n = 3-50$ ; and  $\text{R}_1$  and  $\text{R}_2$  are independently each amino acid side chains comprising the basic-arginine rich region of HIV-1 Tat protein.

2. (Currently amended) A method of inhibiting the binding of Tat protein to Tar RNA comprising introducing the oligourea of claim 1 into a cellular environment *in vitro* wherein the inhibition is sought to occur.
3. (Original) The method of claim 2 wherein the cellular environment is one infected by the HIV-1.
4. (Original) The method of claim 3 wherein the oligourea of claim 1 binds to the TAR RNA of HIV-1, thereby limiting the binding of Tat to TAR RNA.
- 5.-15. (Cancelled)

16. (Currently amended) A composition comprising an oligourea, wherein the oligourea ~~additionally has amino acid side chains which correspond to the basic arginine rich region of the Tat protein.~~ comprises the following structure:



wherein  $n = 3-50$ ; and  $\text{R}_1$  and  $\text{R}_2$  are independently each amino acid side chains comprising the basic-arginine rich region of HIV-1 Tat protein.

17. (Cancelled)
18. (Currently amended) The composition of claim 16 ~~17~~, wherein the  $\text{R}_1$  and  $\text{R}_2$  amino acid side-chains correspond to SEQ ID NO: 1.
19. (Currently amended) The composition of claim 16 ~~18~~, wherein the  $\text{R}_1$  and  $\text{R}_2$  amino acid side-chains correspond to the SEQ ID NO: 1 with a L-Tyr amino acid at the carboxyl-terminus.
- 20.-28. (Cancelled)
29. (New) The oligourea of claim 1, wherein the  $\text{R}_1$  and  $\text{R}_2$  amino acid side chains correspond to SEQ ID NO:1.
30. (New) The oligourea of claim 1, wherein the  $\text{R}_1$  and  $\text{R}_2$  amino acid side chains correspond to SEQ ID NO:1 with a L-Tyr amino acid at the carboxyl-terminus.

Application No.: 09/889,982  
Amendment and Response dated March 17, 2005  
Reply to Office Action of November 17, 2004  
Docket No.: 1368-17 PCT/US  
Page 4

31. (New) The oligourea of claim 1, wherein the  $R_1$  and  $R_2$  amino acid side chains correspond to SEQ ID NO:1 with a L-Tyr amino acid at the amino-terminus.
32. (New) The oligourea of claim 1, wherein n is 5-30.
33. (New) The oligourea of claim 1, wherein n is 8-25.
34. (New) The composition of claim 16, wherein the  $R_1$  and  $R_2$  amino acid side chains correspond to SEQ ID NO:1 with a L-Tyr amino acid at the amino-terminus.